CNS PharmaceuticalsCNSP
About: CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Employees: 3
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
5.42% more ownership
Funds ownership: 11.54% [Q1] → 16.96% (+5.42%) [Q2]
35% less capital invested
Capital invested by funds: $351K [Q1] → $228K (-$123K) [Q2]
47% less funds holding
Funds holding: 19 [Q1] → 10 (-9) [Q2]
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Jason McCarthy 27% 1-year accuracy 4 / 15 met price target | 317%upside $0.50 | Buy Upgraded | 10 Sept 2024 |
Financial journalist opinion
Based on 3 articles about CNSP published over the past 30 days